Shopping Cart 0
Cart Subtotal
AED 0

Duchenne Muscular Dystrophy - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 22020

Details

Duchenne Muscular Dystrophy-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H1 2019, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Duchenne Muscular Dystrophy-Therapeutics DevelopmentPipeline Overview Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 4, 15, 9, 48 and 21 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 9 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Introduction

Duchenne Muscular Dystrophy-Overview

Duchenne Muscular Dystrophy-Therapeutics Development

Duchenne Muscular Dystrophy-Therapeutics Assessment

Duchenne Muscular Dystrophy-Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy-Drug Profiles

Duchenne Muscular Dystrophy-Dormant Projects

Duchenne Muscular Dystrophy-Discontinued Products

Duchenne Muscular Dystrophy-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Advanced Medical Projects, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Akashi Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Anagenesis Biotechnologies, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Antisense Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Avidity Biosciences LLC, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Beech Tree Labs Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Biogen Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Bioleaders Corp, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Biophytis SA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Capricor Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Catabasis Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by CRISPR Therapeutics, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Cumberland Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Dystrogen Therapeutics SA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Editas Medicine Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Eloxx Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Evox Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Fate Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by FibroGen Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Fulcrum Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Galapagos NV, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Italfarmaco SpA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Milo Biotechnology LLC, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Mitobridge Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Mitochon Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by NicOx SA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Novartis AG, H1 2019

Duchenne Muscular Dystrophy-Pipeline by NS Pharma Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by PeptiDream Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Pfizer Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Progenitor Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by PTC Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by ReveraGen BioPharma Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Santhera Pharmaceuticals Holding AG, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Sarepta Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Solid Biosciences Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by SOM Biotech SL, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Strykagen Corp, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Summit Therapeutics Plc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Taiho Pharmaceutical Co Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Teijin Pharma Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Tolerion Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by WAVE Life Sciences Ltd, H1 2019

Duchenne Muscular Dystrophy-Dormant Projects, H1 2019

Duchenne Muscular Dystrophy-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Advanced Medical Projects

Akashi Therapeutics Inc

Anagenesis Biotechnologies

Antisense Therapeutics Ltd

Avidity Biosciences LLC

Beech Tree Labs Inc

Biogen Inc

Bioleaders Corp

Biophytis SA

Capricor Therapeutics Inc

Catabasis Pharmaceuticals Inc

CRISPR Therapeutics

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dystrogen Therapeutics SA

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

Evox Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FibroGen Inc

Fulcrum Therapeutics Inc

Galapagos NV

Italfarmaco SpA

Milo Biotechnology LLC

Mitobridge Inc

Mitochon Pharmaceuticals Inc

NicOx SA

Novartis AG

NS Pharma Inc

PeptiDream Inc

Pfizer Inc

Progenitor Therapeutics Ltd

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

Solid Biosciences Inc

SOM Biotech SL

Strykagen Corp

Summit Therapeutics Plc

Taiho Pharmaceutical Co Ltd

Teijin Pharma Ltd

Tolerion Inc

WAVE Life Sciences Ltd

Company Profile

Company Profile Title

Duchenne Muscular Dystrophy-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H1 2019, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Duchenne Muscular Dystrophy-Therapeutics DevelopmentPipeline Overview Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 4, 15, 9, 48 and 21 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 9 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Introduction

Duchenne Muscular Dystrophy-Overview

Duchenne Muscular Dystrophy-Therapeutics Development

Duchenne Muscular Dystrophy-Therapeutics Assessment

Duchenne Muscular Dystrophy-Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy-Drug Profiles

Duchenne Muscular Dystrophy-Dormant Projects

Duchenne Muscular Dystrophy-Discontinued Products

Duchenne Muscular Dystrophy-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Duchenne Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Advanced Medical Projects, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Akashi Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Anagenesis Biotechnologies, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Antisense Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Avidity Biosciences LLC, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Beech Tree Labs Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Biogen Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Bioleaders Corp, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Biophytis SA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Capricor Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Catabasis Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by CRISPR Therapeutics, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Cumberland Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Dystrogen Therapeutics SA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Editas Medicine Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Eloxx Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Evox Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Fate Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by FibroGen Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Fulcrum Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Galapagos NV, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Italfarmaco SpA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Milo Biotechnology LLC, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Mitobridge Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Mitochon Pharmaceuticals Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by NicOx SA, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Novartis AG, H1 2019

Duchenne Muscular Dystrophy-Pipeline by NS Pharma Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by PeptiDream Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Pfizer Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Progenitor Therapeutics Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by PTC Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by ReveraGen BioPharma Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Santhera Pharmaceuticals Holding AG, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Sarepta Therapeutics Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Solid Biosciences Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by SOM Biotech SL, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Strykagen Corp, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Summit Therapeutics Plc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Taiho Pharmaceutical Co Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Teijin Pharma Ltd, H1 2019

Duchenne Muscular Dystrophy-Pipeline by Tolerion Inc, H1 2019

Duchenne Muscular Dystrophy-Pipeline by WAVE Life Sciences Ltd, H1 2019

Duchenne Muscular Dystrophy-Dormant Projects, H1 2019

Duchenne Muscular Dystrophy-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Advanced Medical Projects

Akashi Therapeutics Inc

Anagenesis Biotechnologies

Antisense Therapeutics Ltd

Avidity Biosciences LLC

Beech Tree Labs Inc

Biogen Inc

Bioleaders Corp

Biophytis SA

Capricor Therapeutics Inc

Catabasis Pharmaceuticals Inc

CRISPR Therapeutics

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dystrogen Therapeutics SA

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

Evox Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FibroGen Inc

Fulcrum Therapeutics Inc

Galapagos NV

Italfarmaco SpA

Milo Biotechnology LLC

Mitobridge Inc

Mitochon Pharmaceuticals Inc

NicOx SA

Novartis AG

NS Pharma Inc

PeptiDream Inc

Pfizer Inc

Progenitor Therapeutics Ltd

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

Solid Biosciences Inc

SOM Biotech SL

Strykagen Corp

Summit Therapeutics Plc

Taiho Pharmaceutical Co Ltd

Teijin Pharma Ltd

Tolerion Inc

WAVE Life Sciences Ltd